scPharmaceuticals (SCPH) Projected to Post Quarterly Earnings on Tuesday

scPharmaceuticals (NASDAQ:SCPH) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $11.63 million for the quarter.

scPharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The business had revenue of $12.15 million during the quarter, compared to analysts’ expectations of $12.08 million. On average, analysts expect scPharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

scPharmaceuticals Stock Performance

scPharmaceuticals stock opened at $2.42 on Monday. The stock has a 50-day simple moving average of $2.64 and a 200 day simple moving average of $3.22. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. scPharmaceuticals has a 12-month low of $1.94 and a 12-month high of $5.65. The stock has a market capitalization of $121.69 million, a price-to-earnings ratio of -1.27 and a beta of 0.17.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Maxim Group cut their price target on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, March 20th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.